Detalles de la búsqueda
1.
The effect of itraconazole on the pharmacokinetics of lorlatinib: results of a phase I, open-label, crossover study in healthy participants.
Invest New Drugs
; 38(1): 131-139, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31728714
2.
Axitinib plasma pharmacokinetics and ethnic differences.
Invest New Drugs
; 33(2): 521-32, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25663295
3.
Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments.
Cancer
; 120(17): 2694-703, 2014 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24844950
4.
Population pharmacokinetic analysis of axitinib in healthy volunteers.
Br J Clin Pharmacol
; 77(3): 480-92, 2014 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23834452
5.
Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial.
Lancet Oncol
; 14(12): 1233-42, 2013 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-24140184
6.
Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer.
Clin Pharmacokinet
; 63(2): 171-182, 2024 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38079095
7.
Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper.
Clin Pharmacol Ther
; 2024 May 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38752712
8.
Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer.
Invest New Drugs
; 30(4): 1531-9, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21670972
9.
Effect of ketoconazole on the pharmacokinetics of axitinib in healthy volunteers.
Invest New Drugs
; 30(1): 273-81, 2012 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-20740300
10.
A literature review of liver function test elevations in rifampin drug-drug interaction studies.
Clin Transl Sci
; 15(7): 1561-1580, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35470578
11.
Evaluation of Lorlatinib Cerebrospinal Fluid Concentrations in Relation to Target Concentrations for Anaplastic Lymphoma Kinase (ALK) Inhibition.
J Clin Pharmacol
; 62(9): 1170-1176, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35373356
12.
Evaluation of the absolute oral bioavailability of the anaplastic lymphoma kinase/c-ROS oncogene 1 kinase inhibitor lorlatinib in healthy participants.
Cancer Chemother Pharmacol
; 89(1): 71-81, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34698901
13.
A Phase I Study to Evaluate the Pharmacokinetics and Safety of Lorlatinib in Adults with Mild, Moderate, and Severe Renal Impairment.
Eur J Drug Metab Pharmacokinet
; 47(2): 235-245, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-35018553
14.
Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics.
Invest New Drugs
; 29(6): 1370-80, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-20596748
15.
Population pharmacokinetic model with time-varying clearance for lorlatinib using pooled data from patients with non-small cell lung cancer and healthy participants.
CPT Pharmacometrics Syst Pharmacol
; 10(2): 148-160, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33449423
16.
The Effect of Modafinil on the Safety and Pharmacokinetics of Lorlatinib: A Phase I Study in Healthy Participants.
Clin Pharmacokinet
; 60(10): 1303-1312, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33937953
17.
Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study.
Clin Pharmacokinet
; 60(10): 1313-1324, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33937954
18.
Phase 1 Study Evaluating the Effects of the Proton Pump Inhibitor Rabeprazole and Food on the Pharmacokinetics of Lorlatinib in Healthy Participants.
Clin Pharmacol Drug Dev
; 10(11): 1395-1404, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34288547
19.
Liver Toxicity Observed With Lorlatinib When Combined With Strong CYP3A Inducers: Evaluation of Cynomolgus Monkey as a Nonclinical Model for Assessing the Mechanism of Combinational Toxicity.
Toxicol Sci
; 182(2): 183-194, 2021 08 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34021354
20.
Correction to: The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants.
Adv Ther
; 37(11): 4754, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32910418